Colgate-Palmolive Company

Under an integrated stress scenario where normalized cycle cost of equity reaches 8.5562%, retailers permanently depress working capital holding baselines, and advertising reinvestment remains elevated in double digits, Colgate's valuation compresses toward the lower bound of $50.65. At the share price of $86.06, trading at a forward P/E of 20.96x, the stock carries a 16.30% premium over Fair value of $74.00, leaving minimal valuation cushion against structural retail pushback or macro cost shocks.

Wide

Colgate-Palmolive possesses a wide economic moat rooted in dominant global oral care market share, entrenched consumer mindshare, and unmatched professional dentist advocacy. The core Oral, Personal and Home Care segment delivered $15,769M in FY2025 revenue, representing 77.37% of consolidated net sales of $20,382M. This foundation is reinforced by Hill's Pet Nutrition ($4,613M in FY2025), which operates a prescription and therapeutic nutrition model driven by clinical veterinary endorsements. Together, these franchises generate consistent, inelastic consumer demand across economic cycles.

Colgate's competitive advantage is reflected in exceptional return metrics, posting a return on invested capital of 38.62% that substantially surpasses its computed moderate cost of equity of 7.20% and computed WACC of 6.90%. The company's pricing power is demonstrated by gross margins reaching 60.11% in FY2025 ($12,251M gross profit on $20,382M revenue) and expanding to 61.48% in Q2 2026 ($3,296M gross profit on $5,361M revenue,). These margins meaningfully exceed consumer defensive peers including Procter & Gamble (50.87%), Kenvue (58.44%), and Archer-Daniels-Midland (6.87%,), confirming structural profitability advantages.

The durability of Colgate's moat is protected by extensive international distribution across more than 200 countries, limiting customer concentration risk. While Walmart Inc represents Colgate's largest retail customer at 11.0% of FY2025 net sales, 89% of revenue is broadly diversified across international supermarkets, independent grocers, pharmacies, and veterinary clinics. Sustained maintenance capital expenditures of $564M in FY2025 (2.77% of revenue) ensure modern supply chain infrastructure and localized manufacturing scale that cannot be easily replicated by regional competitors or private-label manufacturers.

Colgate-Palmolive Company (CL) trades at 21.0x forward earnings against a peer median of 17.1x. Its EV/EBITDA of 15.1x compares with a peer median of 15.3x. The comparison uses 4 peers: The Procter & Gamble Company, Archer-Daniels-Midland Company, Kenvue Inc. and The Estee Lauder Companies Inc., as of 2026-09-27.

We recommend reducing exposure to Colgate-Palmolive Company. At $86.06 on September 25, 2026, the stock trades at a 16.3% premium over our Fair value of $74.00,. While Colgate is an exemplary consumer defensive business with an enviable 38.62% return on invested capital, current pricing already reflects an aggressive operational recovery, leaving zero margin of safety against retail inventory compression.^1,3,4

Investors should capitalize on current trading multiples (20.96x forward P/E) to lock in gains and redeploy into consumer defensive peers offering wider margins of safety or higher cash yields. Maintain trailing stop-losses and monitor retail shipment recovery in upcoming quarters.